In brief
- Botulinum toxin temporarily reduces nerve signals to selected muscles or glands; the expected benefit depends on the exact product and indication.
- In the United States, the current BOTOX Cosmetic label covers temporary improvement of moderate-to-severe glabellar lines, crow’s-feet lines, forehead lines and vertical platysma bands in adults. Forehead treatment has specific label instructions, including treatment with the glabellar area.
- BOTOX also has medical indications that include chronic migraine prevention, severe primary underarm sweating when topical treatment is insufficient, certain bladder disorders, spasticity, cervical dystonia, blepharospasm and strabismus.
- Bruxism, masseter slimming, lip flip, gummy smile, “baby Botox,” mesobotox and many jawline techniques are not FDA-approved BOTOX Cosmetic indications. They may be off-label, and evidence, dosing and risks vary.
- Every botulinum toxin product carries a boxed warning about possible distant spread of toxin effect. Product authenticity, current authorization and qualified administration matter.
Benefits of Botox: aesthetic and medical uses, with the important distinctions
Botulinum toxin is widely used in both aesthetic medicine and several medical specialties. The 2024 ISAPS survey estimated about 7.9 million botulinum toxin procedures performed by plastic surgeons worldwide. Popularity, however, does not mean that every advertised technique is approved, equally supported, or appropriate for every patient.
“Botox” is a brand name, not the generic name of the treatment. BOTOX and BOTOX Cosmetic contain onabotulinumtoxinA. DYSPORT contains abobotulinumtoxinA, and XEOMIN contains incobotulinumtoxinA. Their units, approved uses and dosing instructions are product-specific and cannot be converted from one brand to another.
First: Botox is not a generic category
Botulinum toxin products are prescription drugs with different formulations and regulatory labels. A use approved for one product or in one country cannot be assumed to apply to another product or to Mexico.
For patients in Mexico, the relevant question is not simply whether “Botox is approved.” The exact product, presentation and intended use should be checked against its current COFEPRIS sanitary registration. FDA labeling is useful context, but it does not establish Mexican authorization. COFEPRIS has also issued alerts about falsified and irregularly marketed BOTOX products, which is why traceable supply through authorized channels is essential.
For a broader explanation of mechanism and brands, see /blogs/botox-que-es.
Aesthetic benefits supported by authorized labeling
Expression lines
The current U.S. BOTOX Cosmetic label describes temporary improvement in adults with moderate-to-severe:
- Glabellar lines between the eyebrows.
- Lateral canthal lines, commonly called crow’s feet.
- Horizontal forehead lines associated with frontalis activity.
These treatments reduce activity in selected muscles, which can soften movement-related lines while the effect lasts. They do not stop skin aging, restore lost facial volume or guarantee that future static wrinkles will not develop.
Forehead treatment deserves special care. The BOTOX Cosmetic label recommends treating forehead lines together with glabellar lines to reduce the potential for brow ptosis. The dose and injection map belong to the prescribing information and a clinician’s anatomical assessment—not to a consumer dosing chart. See our focused guide at /blogs/arrugas-en-la-frente.
Vertical platysma bands
The current U.S. BOTOX Cosmetic label also includes temporary improvement of moderate-to-severe vertical bands connecting the jaw and neck in adults. This approved indication should not be confused with every treatment marketed as a “Nefertiti lift.” Injections along the jawline or other neck patterns may fall outside a product’s authorized use.
What “preventive Botox” can and cannot promise
Reducing muscle activity can decrease skin folding while the medicine is active. That does not prove that starting treatment at age 25, using repeated low doses, or following a fixed four-to-six-month schedule will prevent facial aging.
There is no universal age to begin cosmetic botulinum toxin. Treatment should be based on the lines that concern you, facial anatomy, health history, goals, the exact product label and an informed discussion of alternatives. “Baby Botox” is a marketing term, not an FDA-defined indication or standardized dose.
Frequently advertised off-label aesthetic uses
Clinicians may sometimes prescribe an approved drug outside its authorized indication. That is called off-label use. It is not automatically improper, but it requires a clear explanation that the product or anatomical use is not approved for that purpose, along with an honest discussion of evidence, alternatives and added risks.
| Advertised use | Regulatory and patient-safety context |
|---|---|
| Brow shaping or “chemical brow lift” | Injection patterns vary and may cause asymmetry or brow/eyelid droop. It is not a standardized BOTOX Cosmetic indication. |
| Gummy smile | Often off-label. Excess effect can alter the smile, speech or lip function. There is no universal dose. |
| Lip flip | Often off-label. It may affect drinking, speaking, smiling or oral control, and the result is temporary. |
| Masseter slimming | Off-label under the U.S. BOTOX Cosmetic label. Changes in chewing strength, smile symmetry and facial contour must be discussed. |
| Bruxism or jaw pain | Not an FDA-approved BOTOX indication. Diagnosis and management should include dental or orofacial evaluation. |
| “Baby Botox” | Non-standardized marketing term. A lower dose is not automatically safer or more appropriate. |
| Mesobotox or intradermal “pore reduction” | Off-label technique with non-standardized dilution and uncertain benefit. Claims that it closes pores or predictably controls sebum should not be guaranteed. |
| Nefertiti lift or jawline injections | Do not assume that the approved vertical platysma-band indication covers every jawline or neck injection pattern. |
The same distinction applies in Mexico: verify the current COFEPRIS registration and whether the proposed anatomical use is authorized. If it is off-label, that should be disclosed before consent.
Medical benefits of onabotulinumtoxinA
Medical uses should be diagnosed and managed by the relevant specialist. The following examples refer to the U.S. BOTOX label; other products and Mexican authorizations may differ.
Chronic migraine
BOTOX is indicated to prevent headaches in adults with chronic migraine who have 15 or more headache days per month, with headaches lasting four hours a day or longer. It is not established for episodic migraine with 14 or fewer headache days per month. Treatment uses a specialist protocol and is generally repeated no sooner than every 12 weeks.
This is preventive treatment, not an emergency treatment for an active migraine attack. A neurologic assessment is needed to confirm the diagnosis and discuss other preventive options.
Severe primary axillary hyperhidrosis
BOTOX is indicated for severe primary underarm sweating that is not adequately managed with topical medicines. The label does not establish safety and effectiveness for severe sweating in other body areas such as the palms, soles or scalp.
Benefit can last longer than facial cosmetic effects, but there is no universal six-to-twelve-month promise. Retreatment is based on symptom return, product labeling and clinical assessment. See /blogs/botox-axila-hiperhidrosis.
Spasticity, cervical dystonia and eye-muscle disorders
Depending on the product and patient’s age, authorized uses include spasticity, cervical dystonia, blepharospasm and strabismus. These are specialist treatments with indication-specific doses, muscles and safety considerations. Units from one botulinum toxin product cannot be substituted or converted to another.
Overactive bladder and neurologic detrusor overactivity
BOTOX has indications for certain adults with overactive bladder or urinary incontinence related to neurologic disease when an anticholinergic medicine is inadequate or cannot be taken. These are not the same indication or dose. Treatment carries risks that include urinary retention, urinary tract infection and the possible need for catheterization, so it requires urologic evaluation.
Bruxism and masseter pain
Botulinum toxin is used off-label by some clinicians for bruxism or masseter-related pain, but it is not an FDA-approved BOTOX indication. A blog should not promise protection from dental wear, a fixed pain-relief timeline or a standard masseter dose. Bruxism can have dental, sleep-related and behavioral contributors, and treatment may include dental appliances or other approaches. See /blogs/botox-para-bruxismo.
How quickly does it work, and how long does it last?
Onset and duration vary by product, indication and patient. MedlinePlus notes that benefit may take a few days to several weeks and that additional injections are often given every three to four months for several uses. Underarm sweating and some bladder indications may have longer retreatment intervals.
These are not promises. Repeat treatment should be based on symptom return, the approved minimum interval and medical assessment. More frequent treatment, higher doses or switching brands should never be decided by converting units from an online table.
Safety, contraindications and urgent warning signs
Botulinum toxin is a prescription treatment with well-characterized benefits and real risks. Common local effects can include pain, tenderness, swelling, redness or bruising. Depending on the site, headache, neck discomfort, dry eye, temporary brow or eyelid droop, asymmetry or weakness of a nearby muscle can occur.
All botulinum toxin products carry a boxed warning that effects may spread beyond the injection site. Seek urgent medical care for difficulty swallowing, speaking or breathing, generalized muscle weakness, double or blurred vision, or significant eyelid droop after treatment. Symptoms can appear hours to weeks after injection.
Formal contraindications for BOTOX and BOTOX Cosmetic include hypersensitivity to a botulinum toxin preparation or its ingredients and infection at the planned injection site. Bladder treatment has additional contraindications. Neuromuscular disease, swallowing or breathing problems, pregnancy, breastfeeding and interacting medicines require specific medical review; they should not all be mislabeled as formal contraindications.
Before treatment, tell the clinician about every prescription and over-the-counter medicine, vitamin and supplement, including blood thinners, muscle relaxants, injected antibiotics and any botulinum toxin received in the previous months. Do not stop a prescribed anticoagulant or any other prescribed medicine unless the clinician who manages it tells you to do so.
Use a traceable product from an authorized channel and a licensed healthcare professional trained in the exact product, anatomy and management of complications.
Who may benefit?
A consultation can determine whether the expected benefit is reasonable for your concern. Appropriate candidates may include adults seeking temporary improvement of an authorized cosmetic indication or patients with a properly diagnosed medical condition covered by the exact product’s label.
Being young, wanting “prevention,” or seeing a technique on social media is not by itself an indication. A good evaluation covers your goals, baseline movement, eyebrow and eyelid position, medical history, medicines, prior toxin exposure, pregnancy or breastfeeding, and whether the proposed use is approved or off-label.
Sources
- International Society of Aesthetic Plastic Surgery. ISAPS Global Survey 2024. https://www.isaps.org/media/razfvmsk/isaps-global-survey-2024.pdf
- U.S. Food and Drug Administration. BOTOX and BOTOX Cosmetic (onabotulinumtoxinA) Prescribing Information and Medication Guide. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103000s5316s5319s5323s5326s5331lbl.pdf
- U.S. Food and Drug Administration. DYSPORT (abobotulinumtoxinA) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125274Orig1s123correctedlbl.pdf
- U.S. Food and Drug Administration. XEOMIN (incobotulinumtoxinA) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125360s099lbl.pdf
- U.S. Food and Drug Administration. Dermal Filler Do’s and Don’ts for Wrinkles, Lips and More. https://www.fda.gov/consumers/consumer-updates/dermal-filler-dos-and-donts-wrinkles-lips-and-more
- American Academy of Dermatology. Botulinum toxin therapy: Overview. https://www.aad.org/public/cosmetic/wrinkles/botulinum-toxin-overview
- American Academy of Dermatology. Botulinum toxin therapy: FAQs. https://www.aad.org/public/cosmetic/wrinkles/botulinum-toxin-faqs
- MedlinePlus. OnabotulinumtoxinA Injection. https://medlineplus.gov/druginfo/meds/a608013.html
- COFEPRIS. Listados de Registros Sanitarios de Medicamentos. https://www.gob.mx/cofepris/documentos/registros-sanitarios-medicamentos
- COFEPRIS. Actualización sobre la falsificación y comercialización irregular de BOTOX 100 U. https://www.gob.mx/cms/uploads/attachment/file/918239/Alerta_sanitaria_de_Botox_27052024.pdf
Reviewed by our medical team
Dra. Jessica Tapia
Medical Director
Clinical content on this blog is reviewed by the Juvenalia Brío medical team for scientific accuracy and consistency with the care we provide.
